Cognitive and functional patterns of nondemented subjects with equivocal visual amyloid PET findings

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 42, Issue 9, 2015, Pages 1459-1468

  Payoux, P ^a,b,c   Delrieu, J ^a,b   Gallini, A ^a,b,c   Adel, D ^b   Salabert, A S ^b   Hitzel, A ^a,c   Cantet, C ^a,b,c   Tafani, M ^a,b,c   De Verbizier, D ^d   Darcourt, J ^e,f   Fernandez, Ph ^g,h   Monteil, J ^i,j   Carrie I ^a   Voisin, T ^a,b,c   Gillette Guyonnet, S ^a,b,c   Pontecorvo, M ^k   Vellas, B ^a,b,c   Andrieu, S ^a,b,c,l  

^a CHU PURPAN   (France)

^b INSERM   (France)

^c UNIVERSITÉ PAUL SABATIER   (France)

^d MONTPELLIER UNIVERSITY HOSPITAL   (France)

^e CENTRE ANTOINE LACASSAGNE   (France)

^f UNIVERSITÉ CÔTE D'AZUR   (France)

^g BORDEAUX UNIVERSITY HOSPITAL   (France)

^h UMR 5287   (France)

ⁱ LIMOGES UNIVERSITY HOSPITAL   (France)

^j UNIVERSITY OF LIMOGES   (France)

^k AVID RADIOPHARMACEUTICALS   (United States)

^l TOULOUSE UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Alzheimer's disease; Amyloid imaging; Elderly; MAPT trial; PET

Indexed keywords

AMYLOID; FLORBETAPIR F 18;

AGED; ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; COGNITION; CONSENSUS; DAILY LIFE ACTIVITY; DEMENTIA; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; PET-CT SCANNER; PHYSICAL PERFORMANCE; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; RECALL; VERY ELDERLY; ALZHEIMER DISEASE; CONTROLLED STUDY; METABOLISM; OBSERVER VARIATION; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SCINTISCANNING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID; COGNITION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; OBSERVER VARIATION; POSITRON-EMISSION TOMOGRAPHY;

EID: 84937814001     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-015-3067-9     Document Type: Article

References (33)

1. Risacher SL, Saykin AJ. Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection. Annu Rev Clin Psychol. 2013;9:621–48. doi:10.1146/annurev-clinpsy-050212-185535.
2. Tolboom N, Yaqub M, van der Flier WM, Boellaard R, Luurtsema G, Windhorst AD, et al. Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. J Nucl Med. 2009;50:191–7. doi:10.2967/jnumed.108.056499.
3. Kemppainen NM, Aalto S, Wilson IA, Nagren K, Helin S, Bruck A, et al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology. 2007;68:1603–6. doi:10.1212/01.wnl.0000260969.94695.56.
4. Wolk DA, Zhang Z, Boudhar S, Clark CM, Pontecorvo MJ, Arnold SE. Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. J Neurol Neurosurg Psychiatry. 2012;83:923–6. doi:10.1136/jnnp-2012-302548.
5. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305:275–83. doi:10.1001/jama.2010.2008.
6. Choi SR, Schneider JA, Bennett DA, Beach TG, Bedell BJ, Zehntner SP, et al. Correlation of amyloid PET ligand florbetapir F18 binding with Abeta aggregation and neuritic plaque deposition in postmortem brain tissue. Alzheimer Dis Assoc Disord. 2012;26:8–16. doi:10.1097/WAD.0b013e31821300bc.
7. Camus V, Payoux P, Barre L, Desgranges B, Voisin T, Tauber C, et al. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging. 2012;39:621–31. doi:10.1007/s00259-011-2021-8.
8. Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011;68:1404–11. doi:10.1001/archneurol.2011.150.
9. Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010;51:913–20. doi:10.2967/jnumed.109.069088.
10. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67:122–31. doi:10.1002/ana.21843.
11. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31:1275–83. doi:10.1016/j.neurobiolaging.2010.04.007.
12. Morris JC, Price JL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci. 2001;17:101–18.
13. Johnson KA, Sperling RA, Gidicsin CM, Carmasin JS, Maye JE, Coleman RE, et al. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement. 2013;9:S72–83. doi:10.1016/j.jalz.2012.10.007.
14. Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, et al. Performance characteristics of amyloid PET with florbetapir F18 in patients with Alzheimer's disease and cognitively normal subjects. J Nucl Med. 2012;53:378–84. doi:10.2967/jnumed.111.090340.
15. Grundman M, Pontecorvo MJ, Salloway SP, Doraiswamy PM, Fleisher AS, Sadowsky CH, et al. Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimer Dis Assoc Disord. 2013;27:4–15. doi:10.1097/WAD.0b013e318279d02a.
16. Carrie I, van Kan GA, Gillette-Guyonnet S, Andrieu S, Dartigues JF, Touchon J, et al. Recruitment strategies for preventive trials. The MAPT study (MultiDomain Alzheimer Preventive Trial). J Nutr Health Aging. 2012;16:355–9.
17. Gillette-Guyonnet S, Andrieu S, Dantoine T, Dartigues JF, Touchon J, Vellas B, et al. Commentary on "A roadmap for the prevention of dementia II. Leon Thal Symposium 2008." The Multidomain Alzheimer Preventive Trial (MAPT): a new approach to the prevention of Alzheimer's disease. Alzheimers Dement. 2009;5:114–21. doi:10.1016/j.jalz.2009.01.008.
18. Vellas B, Carrie I, Gillette-Guyonnet S, Touchon J, Dantoine T, Dartigues JF, et al. MAPT study: a multidomain approach for preventing Alzheimer’s disease: design and baseline data. J Prevent Alzheimer’s Dis. 2014;1:13–22.
19. Nourhashemi F, Andrieu S, Gillette-Guyonnet S, Vellas B, Albarede JL, Grandjean H. Instrumental activities of daily living as a potential marker of frailty: a study of 7364 community-dwelling elderly women (the EPIDOS study). J Gerontol A Biol Sci Med Sci. 2001;56:M448–53.
20. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179–86.
21. Grober E, Buschke H, Crystal H, Bang S, Dresner R. Screening for dementia by memory testing. Neurology. 1988;38:900–3.
22. Cardebat D, Doyon B, Puel M, Goulet P, Joanette Y. Formal and semantic lexical evocation in normal subjects. Performance and dynamics of production as a function of sex, age and educational level. Acta Neurol Belg. 1990;90:207–17.
23. Wechsler D. Manual for the Wechsler adult intelligence scale – revised. New York: Psychological Corporation; 1981.
24. Reitan R. Validity of the trail making test as an indication of organic brain damage. Percept Mot Skills. 1958;8:271–6.
25. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.
26. Guralnik JM, Ferrucci L, Pieper CF, Leveille SG, Markides KS, Ostir GV, et al. Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. J Gerontol A Biol Sci Med Sci. 2000;55:M221–31.
27. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146–56.
28. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982;17:37–49.
29. Klein G, Chiao P, Barakos J, Purcell D, Sampat M, Oh J, et al. Concordance of quantitative SUVr methods with visual assessment of florbetapir PET screening results. Alzheimers Dement. 2014;10(4 Suppl):P399
30. Nemmi F, Saint-Aubert L, Adel D, Salabert AS, Pariente J, Barbeau EJ, et al. Insight on AV-45 binding in white and grey matter from histogram analysis: a study on early Alzheimer's disease patients and healthy subjects. Eur J Nucl Med Mol Imaging. 2014;41:1408–18. doi:10.1007/s00259-014-2728-4.
31. Chetelat G, Villemagne VL, Pike KE, Ellis KA, Ames D, Masters CL, et al. Relationship between memory performance and beta-amyloid deposition at different stages of Alzheimer's disease. Neurodegener Dis. 2012;10:141–4. doi:10.1159/000334295.
32. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013;12:357–67. doi:10.1016/S1474-4422(13)70044-9.
33. Saint-Aubert L, Nemmi F, Peran P, Barbeau EJ, Payoux P, Chollet F, et al. Comparison between PET template-based method and MRI-based method for cortical quantification of florbetapir (AV-45) uptake in vivo. Eur J Nucl Med Mol Imaging. 2014;41:836–43. doi:10.1007/s00259-013-2656-8.